Targeting the TR4 nuclear receptor with antagonist bexarotene can suppress the proopiomelanocortin signalling in AtT‐20 cells

Drug options for the life‐threatening Cushing's disease are limited, and surgical resection or radiation therapy is not invariably effective. Testicular receptor 4 (TR4) has been identified as a novel drug target to treat Cushing's disease. We built the structure model of TR4 and searched...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Liqun, Shen, Danyang, Zhang, Youyun, Lu, Jieyang, Wang, Mingchao, Wang, Huan, Chen, Yuanlei, Xue, Dingwei, Xie, Dajiang, Li, Gonghui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7933964/
https://www.ncbi.nlm.nih.gov/pubmed/33491272
http://dx.doi.org/10.1111/jcmm.16074

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7933964/
https://www.ncbi.nlm.nih.gov/pubmed/33491272
http://dx.doi.org/10.1111/jcmm.16074

Ejemplares similares